公开(公告)号：US20230295684A1

公开(公告)日：2023-09-21

申请号：US18147360

申请日：2022-12-28

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran

IPC: C12Q1/44 ,  G01N33/68 ,  A61B5/00

CPC classification number: C12Q1/44 ,  A61B5/4064 ,  G01N33/68 ,  G01N2800/40

Abstract: Disclosed herein are methods and systems of determining whether a subject’s levels of GFAP, UCH-L1, or GFAP and UCH-L1 are elevated in a sample collected from the subject. The methods comprise determining whether the levels of GFAP, UCH-L1, or GFAP and UCH-L1 are elevated in the sample, and communicating the determination on or from an instrument. The methods may be used to aid in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head, such as to determine whether the subject is suffering from a mild, moderate, severe, or moderate to severe traumatic brain injury (TBI).

公开(公告)号：US20210389334A1

公开(公告)日：2021-12-16

申请号：US17316257

申请日：2021-05-10

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Jaime Marino

IPC: G01N33/68

Abstract: Disclosed herein are methods of aiding in the diagnosis and evaluation of a subject that has sustained or may have sustained an injury to the head. For example, the present disclosure provides methods for aiding in the diagnosis and evaluation of a subject to determine whether the subject has sustained a traumatic brain injury (TBI) by detecting or measuring a combination of the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) in samples taken at various time points within 48 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：US20210341481A1

公开(公告)日：2021-11-04

申请号：US17316230

申请日：2021-05-10

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Justin Rogers ,  Saul Datwyler ,  Jaime Marino

IPC: G01N33/573 ,  G01N33/68 ,  A61B6/03 ,  A61B6/00

Abstract: Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or moderate to severe traumatic brain injury (TBI), using an early biomarker, ubiquitin carboxy-terminal hydrolase L1 (UCH-L1). Also disclosed here are methods that aid in determining whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1. These methods involve detecting levels and changes in levels of UCH-L1 in one or more samples taken from a human subject at time points within 24 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：US20210102960A1

公开(公告)日：2021-04-08

申请号：US17104886

申请日：2020-11-25

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Justin Rogers ,  Saul Datwyler ,  Jaime Marino

IPC: G01N33/68 ,  G01N33/573

Abstract: Disclosed herein are methods that aid in the hyperacute diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or moderate, severe, or moderate to severe traumatic brain injury (TBI), using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed here are methods that aid in the hyperacute determination of whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1. These methods involve detecting levels of early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a human subject at a time point within about 2 hours, such as about 10, 12, or 20 minutes, after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：US10849548B2

公开(公告)日：2020-12-01

申请号：US15993588

申请日：2018-05-30

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Frederick Korley ,  Agim Beshiri ,  Jaime Marino ,  Saul Datwyler

IPC: A61K38/00 ,  C12Q1/68 ,  G01N33/567 ,  A61B5/00 ,  G01N33/68 ,  G01N33/543 ,  G01N33/577 ,  C12Q1/6883 ,  G01N33/533 ,  G01N33/564

Abstract: Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or a moderate, severe, or moderate to severe traumatic brain injury (TBI), by detecting levels of cardiac troponin I (cTnI) and one or more early biomarkers which are not cTnI, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof, in biological samples taken from a human subject at time points within about 24 hours of injury after the subject has sustained or may have sustained the injury to the head.

公开(公告)号：US12092647B2

公开(公告)日：2024-09-17

申请号：US17099668

申请日：2020-11-16

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Justin Rogers ,  Jaime Marino ,  Raj Chandran ,  Tianming Zhang ,  Saul Datwyler

IPC: G01N33/68 ,  A61B5/00 ,  A61B5/055 ,  A61B6/03 ,  A61B6/50

CPC classification number: G01N33/6893 ,  A61B5/0042 ,  A61B5/055 ,  A61B6/03 ,  G01N33/6896 ,  A61B6/032 ,  A61B6/501 ,  G01N2333/914 ,  G01N2333/918 ,  G01N2800/28 ,  G01N2800/40 ,  G01N2800/60

Abstract: Disclosed herein are methods that aid in the determination of whether to perform imaging, such as magnetic resonance imaging (MRI) or computerized tomography (CT) scan, on a human subject that has sustained or may have sustained an injury to the head using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. These methods involve detecting levels and changes in levels of UCH-L1 in samples taken from a human subject at time points within 24 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：US12085567B2

公开(公告)日：2024-09-10

申请号：US17095695

申请日：2020-11-11

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Justin Rogers ,  Saul Datwyler ,  Jaime Marino

IPC: G01N33/573 ,  A61B6/03 ,  A61B6/50 ,  G01N33/68

CPC classification number: G01N33/573 ,  A61B6/032 ,  A61B6/501 ,  G01N33/6896 ,  G01N2333/46 ,  G01N2333/916 ,  G01N2333/948 ,  G01N2800/28

Abstract: Disclosed herein are methods that aid in the hyperacute diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild, moderate, severe, or moderate to severe traumatic brain injury (TBI), using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed here are methods that aid in the hyperacute determination of whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1. These methods involve detecting changes of levels of an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a human subject at a time point within about 2 hours, such as about 10, 12, or 20 minutes, after the subject has sustained or may have sustained an injury to the head and a second time point about 3 hours to about 6 hours after the first sample is taken.

公开(公告)号：US20230258661A1

公开(公告)日：2023-08-17

申请号：US18147420

申请日：2022-12-28

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Hongwei Zhang

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N2800/2871 ,  G01N2800/60 ,  G01N2333/916 ,  G01N2333/47 ,  C12Y301/02015

Abstract: Disclosed herein are methods and systems of determining whether a subject's levels of GFAP, UCH-L1, or GFAP and UCH-L1 are elevated in a sample collected from the subject. The methods comprise determining whether the levels of GFAP, UCH-L1, or GFAP and UCH-L1 are elevated in the sample, and communicating the determination on or from an instrument. The methods may be used to aid in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head, such as to determine whether the subject is suffering from a mild, moderate, severe, or moderate to severe traumatic brain injury (TBI).

公开(公告)号：US20220381796A1

公开(公告)日：2022-12-01

申请号：US17747397

申请日：2022-05-18

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran

IPC: G01N33/68

Abstract: Disclosed herein are methods, and kits for use in said methods, that aid in the diagnosis and evaluation of a pediatric subject for traumatic brain injury (TBI), using ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed herein are methods, and kits for use in said methods, that aid in determining whether a pediatric subject would benefit from and thus receive an imaging procedure, such as MRI or head computerized tomography (CT) scan based on the levels of GFAP, UCH-L1 or GFAP and UCH-L1.

公开(公告)号：US20210302441A1

公开(公告)日：2021-09-30

申请号：US17224685

申请日：2021-04-07

Applicant: Abbott Laboratories ,  Cedars-Sinai Medical Center

Inventor： Jennifer Van Eyk ,  Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Vidya Venkatraman ,  Shenyan Zhang

IPC: G01N33/68

Abstract: The present disclosure relates to methods for diagnosing and evaluating a subject that has sustained or may have sustained an injury to the head, such as a traumatic brain injury (TBI). In particular, the present disclosure identifies various biomarkers, the detection and/or differential expression of which can be used to assess the presence or absence of a TBI in a subject, and can be used as a basis for diagnosing a subject as having a specific type of TBI (e.g., severe TBI or subclasses of mild TBI). The various TBI biomarkers can be detected individually or in combination and can be used as an important diagnostic, prognostic, and/or TBI risk stratification tool as part of assessing a subject's TBI status.